CoChat
Sign Up
Cited by 298Cancer Mechanisms and TherapyProtein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

Montero, Juan Carlos, Seoane, Samuel, Ocaña, Alberto, Pandiella, Atanasio·2011·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-10-2616
Open this paper in CoChat — free account

Abstract

Dasatinib is a small molecule tyrosine kinase inhibitor that targets a wide variety of tyrosine kinases implicated in the pathophysiology of several neoplasias. Among the most sensitive dasatinib targets are ABL, the SRC family kinases (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK), and the receptor tyrosine kinases c-KIT, platelet-derived growth factor receptor (PDGFR) α and β, discoidin domain receptor 1 (DDR1), c-FMS, and ephrin receptors. Dasatinib inhibits cell duplication, migration, and invasion, and it triggers apoptosis of tumoral cells. As a consequence, dasatinib reduces tumoral mass and decreases the metastatic dissemination of tumoral cells. Dasatinib also acts on the tumoral microenvironment, which is particularly important in the bone, where dasatinib inhibits osteoclastic activity and favors osteogenesis, exerting a bone-protecting effect. Several preclinical studies have shown that dasatinib potentiates the antitumoral action of various drugs used in the oncology clinic, paving the way for the initiation of clinical trials of dasatinib in combination with standard-of-care treatments for the therapy of various neoplasias. Trials using combinations of dasatinib with ErbB/HER receptor antagonists are being explored in breast, head and neck, and colorectal cancers. In hormone receptor–positive breast cancer, trials using combinations of dasatinib with antihormonal therapies are ongoing. Dasatinib combinations with chemotherapeutic agents are also under development in prostate cancer (dasatinib plus docetaxel), melanoma (dasatinib plus dacarbazine), and colorectal cancer (dasatinib plus oxaliplatin plus capecitabine). Here, we review the preclinical evidence that supports the use of dasatinib in combination for the treatment of solid tumors and describe various clinical trials developed following a preclinical rationale. Clin Cancer Res; 17(17); 5546–52. ©2011 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2616

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 54

  1. Lombardo, 2004, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J Med Chem, 47, 6658, 10.1021/jm049486a · DOI
  2. Lindauer, 2010, Dasatinib, Recent Results Cancer Res, 184, 83, 10.1007/978-3-642-01222-8_7 · DOI · Paper page
  3. Finn, 2007, Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro, Breast Cancer Res Treat, 105, 319, 10.1007/s10549-006-9463-x · DOI
  4. Pichot, 2009, Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells, Br J Cancer, 101, 38, 10.1038/sj.bjc.6605101 · DOI
  5. Nautiyal, 2009, Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling, Cancer Lett, 283, 143, 10.1016/j.canlet.2009.03.035 · DOI
  6. Okamoto, 2010, Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition, Mol Cancer Ther, 9, 1188, 10.1158/1535-7163.MCT-10-0002 · DOI
  7. Nagaraj, 2010, Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis, Mol Cancer Ther, 9, 2322, 10.1158/1535-7163.MCT-09-1212 · DOI
  8. Johnson, 2005, Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells, Clin Cancer Res, 11, 6924, 10.1158/1078-0432.CCR-05-0757 · DOI
  9. Guerrouahen, 2010, Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias, Clin Cancer Res, 16, 1149, 10.1158/1078-0432.CCR-09-2416 · DOI
  10. Kurebayashi, 2010, Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype, BMC Cancer, 10, 568, 10.1186/1471-2407-10-568 · DOI
  11. Shor, 2007, Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival, Cancer Res, 67, 2800, 10.1158/0008-5472.CAN-06-3469 · DOI
  12. Park, 2008, Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model, Cancer Res, 68, 3323, 10.1158/0008-5472.CAN-07-2997 · DOI
  13. Trevino, 2006, Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model, Am J Pathol, 168, 962, 10.2353/ajpath.2006.050570 · DOI
  14. Metcalf, 2002, Targeting protein kinases for bone disease: discovery and development of Src inhibitors, Curr Pharm Des, 8, 2049, 10.2174/1381612023393323 · DOI
  15. Id Boufker, 2010, The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts, BMC Cancer, 10, 298, 10.1186/1471-2407-10-298 · DOI
  16. Lee, 2010, Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts, Oncogene, 29, 3196, 10.1038/onc.2010.73 · DOI
  17. Araujo, 2009, Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation, Cancer Biol Ther, 8, 2153, 10.4161/cbt.8.22.9770 · DOI
  18. Vandyke, 2009, Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis, Leukemia, 23, 994, 10.1038/leu.2008.356 · DOI
  19. Belsches-Jablonski, 2001, Src family kinases and HER2 interactions in human breast cancer cell growth and survival, Oncogene, 20, 1465, 10.1038/sj.onc.1204205 · DOI
  20. Ishizawar, 2007, c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function, Oncogene, 26, 3503, 10.1038/sj.onc.1210138 · DOI
  21. Zhang, 2011, Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways, Nat Med, 17, 461, 10.1038/nm.2309 · DOI · Paper page
  22. Seoane, 2010, Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells, J Natl Cancer Inst, 102, 1432, 10.1093/jnci/djq315 · DOI
  23. Koppikar, 2008, Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma, Clin Cancer Res, 14, 4284, 10.1158/1078-0432.CCR-07-5226 · DOI
  24. Bardelli, 2010, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J Clin Oncol, 28, 1254, 10.1200/JCO.2009.24.6116 · DOI · Paper page
  25. Premkumar, 2010, Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells, J Carcinog, 9, 7, 10.4103/1477-3163.65448 · DOI
  26. Jaganathan, 2010, Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src, J Pharmacol Exp Ther, 333, 373, 10.1124/jpet.109.162669 · DOI
  27. Premkumar, 2010, Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines, Int J Oncol, 37, 633
  28. Nagaraj, 2011, Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth, Clin Cancer Res, 17, 483, 10.1158/1078-0432.CCR-10-1670 · DOI
  29. Tryfonopoulos, 2011, Src: a potential target for the treatment of triple-negative breast cancer, Ann Oncol, 10.1093/annonc/mdq757 · DOI
  30. Levitt, 2010, Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling, Mol Cancer Ther, 9, 1128, 10.1158/1535-7163.MCT-10-0096 · DOI
  31. Du, 2009, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy, Nat Biotechnol, 27, 77, 10.1038/nbt.1513 · DOI
  32. Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 · DOI
  33. Zhang, 2009, Latent bone metastasis in breast cancer tied to Src-dependent survival signals, Cancer Cell, 16, 67, 10.1016/j.ccr.2009.05.017 · DOI
  34. Moulder, 2010, Development of candidate genomic markers to select breast cancer patients for dasatinib therapy, Mol Cancer Ther, 9, 1120, 10.1158/1535-7163.MCT-09-1117 · DOI
  35. Varricchio, 2007, Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide, Mol Cancer Res, 5, 1213, 10.1158/1541-7786.MCR-07-0150 · DOI
  36. Migliaccio, 1996, Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells, EMBO J, 15, 1292, 10.1002/j.1460-2075.1996.tb00471.x · DOI
  37. Hiscox, 2006, Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer, Endocr Relat Cancer, 13, S53, 10.1677/erc.1.01297 · DOI
  38. Riggins, 2006, Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b, Cancer Res, 66, 7007, 10.1158/0008-5472.CAN-05-3952 · DOI
  39. Mayer, 2009, Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088, J Clin Oncol, 27, 1011, 10.1200/jco.2009.27.15_suppl.1011 · DOI
  40. Cortes, 2009, Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy data from phase 1 study CA180-004, Cancer Res, 69, S676, 10.1158/0008-5472.SABCS-09-3092 · DOI
  41. Fornier, 2010, Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): a phase I/II study, J Clin Oncol, 28, 1156, 10.1200/jco.2010.28.15_suppl.1156 · DOI
  42. Tatarov, 2009, SRC family kinase activity is up-regulated in hormone-refractory prostate cancer, Clin Cancer Res, 15, 3540, 10.1158/1078-0432.CCR-08-1857 · DOI
  43. Nam, 2005, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells, Cancer Res, 65, 9185, 10.1158/0008-5472.CAN-05-1731 · DOI
  44. Pfitzenmaier, 2003, Characterization of C4-2 prostate cancer bone metastases and their response to castration, J Bone Miner Res, 18, 1882, 10.1359/jbmr.2003.18.10.1882 · DOI
  45. Morrissey, 2007, Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases, BMC Cancer, 7, 148, 10.1186/1471-2407-7-148 · DOI
  46. Koreckij, 2009, Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis, Br J Cancer, 101, 263, 10.1038/sj.bjc.6605178 · DOI
  47. Yu, 2009, Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer, Clin Cancer Res, 15, 7421, 10.1158/1078-0432.CCR-09-1691 · DOI
  48. Araujo, 2009, Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086), J Clin Oncol, 27, 5061, 10.1200/jco.2009.27.15_suppl.5061 · DOI
  49. Liu, 2011, CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis, Proc Natl Acad Sci U S A, 108, 1379, 10.1073/pnas.1017228108 · DOI
  50. Kalinsky, 2010, A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: an Eastern Cooperative Oncology Group study (E2607), J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.tps312 · DOI
  51. Algazi, 2010, A phase I/II trial of DTIC and dasatinib in metastatic melanoma, J Clin Oncol, 28, 8532, 10.1200/jco.2010.28.15_suppl.8532 · DOI
  52. Baker, 2011, The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer, J Natl Cancer Inst, 103, 407, 10.1093/jnci/djq569 · DOI
  53. Mukhopadhyay, 1995, Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation, Nature, 375, 577, 10.1038/375577a0 · DOI
  54. Haura, 2010, Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer, J Clin Oncol, 28, 1387, 10.1200/JCO.2009.25.4029 · DOI

Cited by

Sorted by citations

See all 298

Metadata

Authors
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A.
Affiliations
Consejo Superior de Investigaciones Científicas (ES)
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2011-09-01
Volume
17
Issue
17
Pages
5546-5552
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-10-2616
OpenAlex
W2147545245
Cited by
298
References
5
Citations by year
2026: 13 · 2025: 14 · 2024: 24 · 2023: 14 · 2022: 23 · 2021: 22 · 2020: 22 · 2019: 21 · 2018: 14 · 2017: 18 · 2016: 25 · 2015: 20 · 2014: 22 · 2013: 23 · 2012: 21
FWCI
2.75
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
dasatinib, tyrosine kinase inhibitors, Src family kinases, receptor tyrosine kinase, ABL, CD117, PDGFR, DDR1, c-fms, Eph receptors, combination therapy, solid tumors, breast cancer, prostate cancer, melanoma, colorectal cancer, head and neck cancer, bone microenvironment, osteoclast inhibition, metastasis, apoptosis
MeSH terms
Dasatinib, Antineoplastic Agents, Cell Movement, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Pyrimidines, Thiazoles, Biomarkers, Tumor, Apoptosis, src-Family Kinases, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review